在患有抗脂抗体相关中风的患者中使用抗血小板药物的二次预防
Wookjin Yang1, Matthew Chung2, Jiyeon Ha2
1Department of Neurology, Asan Medical Center, Seoul, Republic of Korea.
Scientific reports
|March 2, 2025
概括
对于患有缺血性中风的抗脂综合征 (APS) 患者,抗血小板疗法如单抗血小板疗法 (SAPT) 和双抗血小板疗法 (DAPT) 显示出对华法林的好处. 这些疗法可能为APS中风预防提供更安全的替代方案.
科学领域:
- 神经学 神经学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 临床指南建议华法林用于抗脂综合征 (APS) 患有缺血性中风的患者,但强有力的证据有限.
- 抗脂抗体 (aPLs) 与血栓事件的风险增加有关,包括中风.
研究的目的:
- 评估不同类型的抗血栓性药物的实际有效性和安全性,用于aPLs患者的二次中风预防.
主要方法:
- 对缺血性中风或过渡性缺血性发作患者的回顾性评估为aPLs阳性.
- 患者按二次预防性抗血栓药物分类:华法林,单抗血小板治疗 (SAPT),双抗血小板治疗 (DAPT) 或直接口服抗凝药.
- 一个时间变化的考克斯比例危险模型分析了复发性血栓和重大出血的复合结果.
主要成果:
- 在167名患者中,28人经历了复合事件. 与华法林相比,SAPT和DAPT显示出显著的临床益处 (aHR分别为0.24和0.25).
- 与华法林 (aHR 0.10) 相比,双重抗血小板治疗 (DAPT) 显示大出血事件显著减少.
- 抗血小板药和华法林组之间,复发性血栓事件的风险类似.
结论:
- 包括SAPT和DAPT在内的抗血小板治疗可能是华法林的安全有效替代品,用于aPL和APS患者的二次中风预防.
- 需要进一步的前性研究来证实这些发现并指导临床实践.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
454
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
454
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
590
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
590
01:22Alzheimer's Disease: Treatment
145
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
145